From concept to cure: Molecular mechanisms, clinical triumphs, and future horizons of chimeric antigen receptor T-cell therapy

作者
Sapna Saini,Neeraja Suresh,Shailendra Dwivedi,Akash Bansal,Shashank Shekhar,Ruchika Agrawal,Sudhir Shyam Kushwaha,Praveen Sharma,Vibha Dutta
标识
DOI:10.4103/ijpmmm.ijpmmm_4_25
摘要

Chimeric antigen receptor (CAR) T-cell therapy is one of the most significant immunotherapeutic strategies for hematological malignancies, achieving durable remission in otherwise refractory cases. This review highlights the fundamental design principles, molecular mechanisms, clinical applications, and global regulatory perspectives of CAR T-cell therapy. The therapy involves ex vivo genetic modification of autologous T-cells to express synthetic receptors that integrate antigen-recognition and intracellular signaling domains, thereby enabling specific and potent cytotoxicity independent of major histocompatibility complex restriction. Successive generations of CAR constructs have incorporated co-stimulatory motifs (CD28, 4-1BB, and OX40), cytokine secretion modules, and signaling adaptors Interleukin-2 (IL-2) receptor beta chain, signal transducer, and activator of transcription 3 to enhance proliferation, persistence, and anti-cancer activity. Mechanistically, CAR T-cells mediate tumor destruction through perforin granzyme-dependent cytolysis, Fas ligand/tumor necrosis factor-alpha-induced apoptosis, and cytokine release, primarily IL-2 and interferon-gamma. The U. S. Food and Drug Administration has approved six CAR T-cell products, namely Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti, mainly targeting CD19 or B-cell maturation antigen antigens. Despite remarkable efficacy in B-cell malignancies, therapeutic challenges remain, including antigen escape, immune-suppressive tumor microenvironment, cytokine release syndrome, neurotoxicity, and high manufacturing cost. Current innovations such as armored CARs, universal allogeneic CARs, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-mediated editing, and artificial intelligence-driven optimization aim to overcome these limitations and expand applications toward solid tumors and autoimmune disorders. A comparative overview of global regulatory frameworks highlights the differences in clinical accessibility and cost-effectiveness across the regions. Collectively, this review provides a comprehensive synthesis of mechanistic insights, technological progress, and translational opportunities in the evolving landscape of CAR T-cell therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
skbz完成签到,获得积分10
刚刚
1秒前
相文杰完成签到,获得积分10
1秒前
GBY发布了新的文献求助10
1秒前
dalong发布了新的文献求助40
2秒前
小奥雄完成签到,获得积分10
2秒前
赵云发布了新的文献求助10
3秒前
3秒前
水煮电吹风的应助被风朝东采纳,获得10
3秒前
华仔的应助被Ariel采纳,获得10
6秒前
Au完成签到 ,获得积分10
6秒前
燕儿完成签到 ,获得积分10
6秒前
细心的平蝶完成签到,获得积分10
7秒前
yssmbf完成签到,获得积分10
7秒前
乐乐的应助被高贵的不凡采纳,获得10
7秒前
yahonyoyoyo发布了新的文献求助30
7秒前
风趣的忆灵完成签到,获得积分10
8秒前
SKY完成签到,获得积分10
8秒前
Code_king发布了新的文献求助10
9秒前
11秒前
王鑫完成签到,获得积分10
11秒前
12秒前
dx完成签到,获得积分10
12秒前
13秒前
慕青的应助被科研通管家采纳,获得10
13秒前
小二郎的应助被w88888z采纳,获得10
13秒前
丘比特的应助被科研通管家采纳,获得10
13秒前
ccq的应助被科研通管家采纳,获得10
13秒前
打打的应助被科研通管家采纳,获得10
14秒前
14秒前
youknowdcf完成签到,获得积分10
14秒前
null的应助被科研通管家采纳,获得10
14秒前
14秒前
星辰大海的应助被科研通管家采纳,获得10
14秒前
杜杨帆发布了新的文献求助10
14秒前
14秒前
Maestro_S的应助被科研通管家采纳,获得10
14秒前
汉堡包的应助被科研通管家采纳,获得10
14秒前
15秒前
天天快乐的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011